Emily Bergsland, MD
Enriched profileProfessor of Clinical Medicine; Director, UCSF Center for Neuroendocrine Tumors · University of California, San Francisco
Emily Bergsland is Professor of Clinical Medicine; Director, UCSF Center for Neuroendocrine Tumors at University of California, San Francisco. OpenAlex indexes 372 publications with 18,399 citations (h-index 56); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Emily Bergsland, MD, is Professor of Clinical Medicine at University of California, San Francisco. The public record shows 372 publications with 18,399 citations (h-index 56), centered on Neuroendocrine Tumor Research Advances, Colorectal Cancer Treatments and Studies, Pituitary Gland Disorders and Treatments. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 5 companies, 3 NIH-funded awards (2004–2026).
- Top research focus: Neuroendocrine Tumor Research Advances
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 140.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Sponsor: University of California, San Francisco
- Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
Sponsor: University of California, San Francisco
- Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Sponsor: University of California, San Francisco
Industry payments
Updated 16 Oct 2026
5 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20251 payment
- TAIHO ONCOLOGY, INC.Program year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20241 payment
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Antidiarrheal microorganisms100%Creon100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
3 NIH research awards on record, funded 2004–2026 per NIH RePORTER. The latest:
- Cancer Research Training and Education Coordination
University of California, San Francisco
FY2026$361,621P30CA082103 - UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology
University of California, San Francisco
FY2025$643,767K12CA260225 - Cancer Research Training and Education Coordination
University of California, San Francisco
FY2025$366,041P30CA082103
Congress activity
Updated 16 Oct 2026
62 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Molecular classification of neuroendocrine carcinoma of the bladder.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2021 - Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms
Endocrine Related Cancer
2021
Most-cited works
by citation count (OpenAlex)Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/emily-bergsland-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
carcinoid.org/emily-bergsland-md-2021-luncheon-with-the-experts-resources
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →carcinoid.org ↗ - Other
cor2ed.com/experts/dr-emily-bergsland
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cor2ed.com ↗ - Other
nanets.net/show-all/233-emily-k-bergsland-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nanets.net ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
Editorial & leadership roles
journal and society appointments- Past President
North American Neuroendocrine Tumor Society (NANETS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗ - Member
NCCN Neuroendocrine Tumor Guidelines panel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗ - Past Chair
NET Task Force, NCI Gastrointestinal Steering Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →amp.profiles.ucsf.edu ↗ - Awards Committee Chair
NANETS
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nanets.net ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nanets.net ↗
Secondary affiliations
appointments beyond the home institution- Associate Director for Education
UCSF Helen Diller Family Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
Media & interviews
press, podcasts and appearances- The ASCO Post profile: Emily Bergsland
specializing in neuroendocrine tumors with a broad focus on collaborative research
2021provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Emmanuelle Waubant, MD
University of California, San Francisco
Joel Palefsky, MD
University of California, San Francisco
Peter Hunt, MD
University of California, San Francisco
Owen Wolkowitz, MD
University of California, San Francisco
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH